Supporting Innovative ALS Treatments with Clene Nanomedicine & Synapticure
October 14, 2024
Anovo is proud to announce a new partnership with Clene Nanomedicine, Inc. and Synapticure Inc., supporting their efforts to bring hope to people living with Amyotrophic Lateral Sclerosis (ALS). As part of this collaboration, Anovo is now dispensing CNM-Au8®, Clene’s innovative gold nanocrystal suspension, for their Early Access Program (EAP) patients.
What is Amyotrophic Lateral Sclerosis (ALS)?
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over time, the disease leads to a loss of muscle control and function, often impacting the ability to move, speak, swallow, and even breathe. The disease has a profound impact on patients and their families, making the search for innovative therapies like CNM-Au8® critical.
Clene Nanomedicine and Synapticure Partner with Anovo
Our collaboration with Clene Nanomedicine and Synapticure underscores our dedication to improving access to promising therapies. By dispensing this treatment through Clene’s Early Access Program, Anovo is helping to ensure patients and families receive the care and support they need to navigate the challenges of ALS.
Related Posts
Nationwide Coverage: Anovo Geographic Reach and Service Consistency
True nationwide specialty pharmacy coverage requires comprehensive infrastructure, robust logistics partnerships, and operational systems designed to overcome geographic challenges. At…
October 24, 2025
Business Continuity Planning: Anovo’s Redundancy and Disaster Recovery
When patients depend on life-changing rare disease therapies, service interruptions can have devastating health consequences. At Anovo, our business continuity…
September 8, 2025
Behind the Delivery: How Anovo’s 3PL/Wholesale Team Keeps Rare Therapies Moving
At Anovo, every team plays a role in delivering hope to patients living with rare diseases. While many think of…
August 20, 2025